Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cardiff Oncology (CRDF) stocks in Canada

Learn how to easily invest in Cardiff Oncology stocks.

Cardiff Oncology is a biotechnology business based in the US. Cardiff Oncology stocks (CRDF.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.66 – a decrease of 15.95% over the previous week. Cardiff Oncology employs 11 staff and has a trailing 12-month revenue of around $344,993.

How to buy shares in Cardiff Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRDF – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cardiff Oncology stock price (NASDAQ:CRDF)

Use our graph to track the performance of CRDF stocks over time.

Cardiff Oncology shares at a glance

Information last updated 2022-01-24.
Latest market close$3.11
52-week range$3.31 - $14.98
50-day moving average $5.79
200-day moving average $6.77
Wall St. target price$23.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.67

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cardiff Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cardiff Oncology price performance over time

Historical closes compared with the close of $3.11 from 2022-01-27

1 week (2022-01-21) -15.95%
1 month (2021-12-29) -47.55%
3 months (2021-10-29) -47.02%
6 months (2021-07-29) -41.65%
1 year (2021-01-29) -73.64%
2 years (2020-01-29) 88.48%
3 years (2019-01-29) 337.72%
5 years (2017-01-27) 55.50%

Cardiff Oncology financials

Revenue TTM $344,993
Gross profit TTM $-10,869,403
Return on assets TTM -17.65%
Return on equity TTM -30.46%
Profit margin 0%
Book value $3.38
Market capitalisation $151.9 million

TTM: trailing 12 months

Cardiff Oncology share dividends

We're not expecting Cardiff Oncology to pay a dividend over the next 12 months.

Have Cardiff Oncology's shares ever split?

Cardiff Oncology's shares were split on a 1:6 basis on 19 February 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cardiff Oncology shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cardiff Oncology shares which in turn could have impacted Cardiff Oncology's share price.

Cardiff Oncology share price volatility

Over the last 12 months, Cardiff Oncology's shares have ranged in value from as little as $3.31 up to $14.98. A popular way to gauge a stock's volatility is its "beta".

CRDF.US volatility(beta: 1.66)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cardiff Oncology's is 1.6564. This would suggest that Cardiff Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Cardiff Oncology overview

Cardiff Oncology, Inc. , a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic colorectal cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. In addition, it develops therapeutics, such as belinostat (Beleodaq); quizartinib (AC220), a development stage FLT3 inhibitor; and bortezomib (Velcade) for the treatment of leukemias, lymphomas, and solid tumor cancers. The company primarily serves pharmaceutical companies. Cardiff Oncology, Inc.

Stocks similar to Cardiff Oncology

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site